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Abstract
Background: HevyLite™ is a new, recently developed method that facilitates separate quantification of the kappa-
and lambda-bounded amounts of a given immunoglobulin (Ig). Using this method, we measured intact
immunoglobulin (heavy/light chain; HLC) IgG-kappa, IgG-lambda, IgA-kappa, IgA-lambda individually, as well as
their deriving ratios (HLCR) in a series of IgG or IgA multiple myeloma (MM) patients, to investigate and assess the
contribution of these tests to disease evaluation.
Patients and methods: HevyLite™ assays were used in sera from 130 healthy individuals (HI) and 103 MM patients, at
time of diagnosis. In patients, the level of paraprotein was IgG in 78 (52 IgG-kappa, 26 IgG-lambda) and IgΑ in 25 (13
IgΑ-kappa, 12 IgΑ-lambda). Durie-Salmon and International Staging System stages were evenly distributed.
Symptomatic patients (n = 77) received treatment while asymptomatic ones (n = 26) were followed. Patients’ median
follow-up was at 32.6 months. HLCR was calculated with the involved Ig (either G or A) as numerator.
Results: In HI, median IgG-kappa was 6.85, IgG-lambda 3.81, IgA-kappa 1.19 and IgA-lambda 0.98 g/L. The
corresponding median involving HLC values in MM patients were 25.8, 23.45, 28.9 and 36.4 g/L. HLC-IgG related to
anemia, high serum free light chain ratio and extensive bone marrow infiltration, while high HLCR correlated with
the same plus increased b2-microglobulin. In addition, increased HLCR and the presence of immunoparesis
correlated with time to treatment. Patients with high HLCR had a significantly shorter survival (p = 0.022); HLCR
retained its prognostic value in multivariate analysis.
Conclusions: HLC and HLCR quantify the precise amount of the involved immunoglobulin more accurately than
other methods; moreover, they carry prognostic information regarding survival in MM patients.
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Introduction
Multiple myeloma (MM) is characterized by bone mar-
row (BM) plasma cell infiltration and the presence of
serum/urine monoclonal immunoglobulin (Ig). Disease
manifestations and behavior vary widely, while survival
ranges from a few months to more than a decade.
Serum monoclonal Ig quantification is part of MM
diagnostic criteria, and one of Durie and Salmon (DS)
staging system’s risk factors [1]. It is also used for moni-
toring response and relapse. However, MM aggressive-
ness is not related to the amount of Ig secretion, and
newer staging systems did not retain Ig quantity as a
risk parameter [2].
The poor utility of IgG and IgA measurements may be
related to the following:1) Changes in hematocrit and
blood volume occur in MM leading serum Ig concentra-
tions to vary by 50% or more, independently of changes
in tumor production [3]; 2) Serum IgG concentrations
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are affected by variable clearance rates, so measurements
do not reliably relate to tumor production. For example,
IgG is recycled many times by neonatal Fc receptors
(FcRn), therefore at normal serum concentration, its
half-life is extended from 3 to 21 days. At higher IgG
concentration, FcRn receptors are saturated, so IgG
half-life is reduced [4]. Thus, clearance rates vary with
different IgG levels. Similar arguments may apply to IgA
measurements [5]. When measuring IgA, proteins such
as transferrin can co-migrate in protein electrophoresis
gels, contributing to falsely elevated results [6].
A new method was recently developed and validated
for the separate quantification of the kappa- and
lambda-bounded amounts of circulating IgG and IgA
[7,8]. This was achieved by developing antibodies target-
ing unique junctional epitopes between the heavy and
light chains of each Ig molecule. Immunoassay such as
Hevylite™ using these antibodies as target has been
manufactured for the analysis of Ig heavy/light chain
(HLC) pairs. The aforementioned assay allows the quan-
tification of the absolute value of the involved IgG,
IgGl, IgA and IgAl separately, along with their deriv-
ing ratios (HLCR): IgG/IgGl, IgGl/IgG, IgA/IgAl
and IgAl/IgA [7].
In paraproteinemias, the “classical” nephelometric
quantification of total “intact” Ig comprises the parapro-
tein per se, and the remaining kappa- and lambda-
bounded Ig of the same class. With the Hevylite™, if
the involved Ig (iHLC) is calculated as a nominator, the
ratio’s (HLCR) denominator represents only polyclonal
intact Ig of the same class (p-HLC), bounded to the
“non-restricted” light chain; the nominator (iHLC) is
made up of the monoclonal protein and the remaining
polyclonal Ig of the same class and light chain restric-
tion, the value of which is much closer to the exact
paraprotein amount than otherwise. In addition,
increased polyclonal suppression leads to HLCR eleva-
tion because of the denominator’s reduction. The pur-
pose of this study was to investigate the contribution of
HLCs and their deriving ratios (HLCR) in a series of
MM patients at diagnosis.
Patients and methods
A. Patients
103 patients characterized by the presence of heavy
chain paraprotein and referred to herein as “intact” Ig
MM patients, were studied at diagnosis. There were 46
women and 57 men with a median age of 67. Of these,
31%, 27% and 42% were in DS stage Ι, ΙΙ and ΙΙΙ respec-
tively, and 36%, 30%, and 34% were stages 1, 2 and 3 by
ΙSS [9]. Anemia (Hb < 10 g/L) was present in 25% of all
patients, with renal failure (creatinine ≥ 2 mg/dl) in
11%, thrombocytopenia (PLT < 140 × 10 [9]/L) in
13.5%, hypoalbuminaemia (alb < 3.5 g/L) in 20.8%,
hypercalcemia in 12.6% and increased LDH (above nor-
mal) in 7%. 26% of these patients presented severe bone
disease (osteolyses with fractures) and 48% had an
extensive BM plasma cell infiltration (≥ 50%). Parapro-
tein type was determined by serum immunofixation,
which was IgG in 78 patients (52 IgG, 26 IgGl) and
IgΑ in 25 (13 IgΑ, 12 IgΑl). Median total paraprotein
level as routinely determined by nephelometry, which
we called “total” paraprotein, was 31.78 g/L for IgG and
29.10 g/L for IgA at presentation. Median free light
chain ratio (FLCR) was 9.44 in kappa-restricted patients
and 19.62 in those who were lambda-restricted.
77 patients were already symptomatic or became
symptomatic during follow up. Symptomatic patients
were treated with conventional modalities. The 26
asymptomatic patients were only followed. Patients’
median follow-up was for 32.6 months.
B. Methods
HLC were determined nephelometry on a Dade Behring
BN II Nephelometer at the Binding Site laboratory in
Birmingham, U.K. Polyclonal sheep antibodies (Hevy-
lite™, Binding Site, U.K.) were used as described [6].
The HLCRs were calculated with the involved intact Ig
as numerator, and the polyclonal intact Ig of the same
class as denominator (IgG/p-IgGl, IgGl/p-IgG,
IgA/p-IgAl and IgAl/p-IgA). Measurements were
reproducible.
Frozen sera from the aforementioned 103 patients,
drawn at the time of diagnosis, were retrospectively ana-
lyzed. In addition, HLC measurements performed in 130
healthy individuals (HI) were used for control values.
We called the presence of hypogammaglobulinemia of
uninvolved Igs systemic immunoparesis (SI); it was
defined using our laboratory lower cut-off values as IgG
< 6.9 g/L and/or IgM < 0.34 g/L in IgA-patients and
IgA < 0.88 g/L and/or IgM < 0.34 g/L in IgG-patients.
Immunoparesis of the same class (ISC) was defined as
any p-HLC value below the 95th percentile range of p-
HLCs in HI sera. Thus, IgGl, IgG, IgAl and IgA
patients were considered to have ISC when their p-
IgG, p-IgGl, p-IgA and p-IgAl were below 4.03 g/L,
1.97 g/L, 0.48 g/L and 0.38 g/L respectively.
“High” HLCR was defined as any value above median.
HLCs and HLCR values were compared with disease
parameters such as beta2-microglobulin (b2Μ), haemo-
globin (Hb), serum albumin (alb), creatinine (cr), hyper-
calcemia, LDH, severe bone disease, serum free light
chains (sFLC) and their ratio (sFLCR), bone marrow
(BM) infiltration and survival.
Statistical analysis was performed using SPSS v15.0.
Hazard ratios and the prognostic significance of “high”
HLCR were determined by univariate Cox regression
analysis. Kaplan Meier method was used for pictorial
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representation of survival and time to treatment. Cate-
gorical variables were compared with the chi square test
(x2).
All sera were obtained with informed consent and the
use of frozen sera for the retrospective evaluation of
HLCs was approved by the local ethical committee.
Results
Hevylite™ assays in HI
In 130 HI, IgG-kappa ranged from 4.03 to 9.78 g/L
(median 6.85), IgG-lambda from 1.97 to 5.71 (median
3.81), IgA-kappa from 0.48 to 2.82 (median 1.19) and
IgA-lambda from 0.36 to 1.98 (median 0.98). The ratio
IgG-kappa/IgG-lambda ranged from 0.98 to 2.75 (med-
ian 1.87), the IgG-lambda/IgG-kappa from 0.37 to 0.893
(median 0.54), the IgA-kappa/IgA-lambda from 0.8 to
2.04 (median 1.27) and the IgA-lambda/IgA-kappa from
0.49 to 1.256 (median 0.79) (Table 1).
Hevylite™ assays in multiple myeloma patients at
diagnosis
Median iHLC in IgG patients was 25.61 g/L; it ranged
from 1.80 to 101 g/L (median 25.8) for iIgG-kappa, and
from 2.27 to 86.3 g/L (median 23.45) for iIgG-lambda.
Median iHLC in IgA patients was 34.9 g/L, ranging
from 5.59 to 71.6 g/L (median 28.9) in iIgA-kappa and
from 7.23 to 60.4 g/L (median 36.4) in iIgA-lambda
patients, respectively. Corresponding correlations with
total IgG and IgA were r = 0.8 and 0.9. All patients had
abnormal HLCR at diagnosis. The median HLCR in
IgG-MM was 21.47, and 72.42 in IgA-MM.
Correlations between disease variables and HLC
measurements
Involved HLC-IgG absolute values above median corre-
lated with Hb ≤ 10 g/L (p = 0.019), BM infiltration >
50% (p = 0.011) and sFLCR above median (p = 0.017),
while iHLC- IgA did not correlate to any disease para-
meters. “High” HLCR correlated with b2Μ > 3.5 mg/L
(p = 0.024), Hb ≤ 10 g/L (p = 0.003), BM infiltration >
50% (p = 0.002) and sFLCR above median (p = 0.004).
SI was present in 76 out of 103 patients, ISC in 83/103
and both in 63/103.
Relationship between HLC measurements and time to
progression
As expected, “high” HLCR correlated with time to treat-
ment (p < 0.001) (Figure 1). This was indeed also the
case for “total” paraprotein. ISC was also associated with
shorter time to treatment (p = 0.032). The same was
true for SI (p = 0.002).(Figure 2A &2B).
Relationship between HLC measurements and overall
survival
Disease variables with an adverse prognostic impact on
survival were Durie and Salmon stage (p = 0.046), ISS
stage (p < 0.001), b2Μ above 3.5 mg/L (p < 0.001), Hb
≤ 10 g/L (p = 0.004), platelet counts ≤ 140 × 10 [9]/L (p
< 0.001), alb < 3.5 g/L (p = 0.015), Cr > 2 mg/dL (p <
0.001), BM plasma cell infiltration > 50% (p < 0.001),
sFLCR above median (p = 0.022) and “high” HLCR
values (p = 0.022) (Figure 3). On the contrary, IgG and
IgA paraprotein levels, HLC, SI, ISC and IgM levels,
were not of any significance with regard to prognosis. In
multivariate analysis, only platelet count, b2M and
HLCR remained significant.
Discussion
In the present study the clinical utility of the new intact
immunoglobulin heavy chain/light chain (Hevylite™)
method was assessed in a series of “intact” Ig MM
patients, studied from the time of diagnosis. Sex, age,
stage groups and clinical manifestations were represen-
tative and equivalent to any other non-selected MM
patients cohort, with the exclusion of light chain and
non-secretory patients. Paraprotein quantification with
Hevylite™ assays correlated with “total” Ig measure-
ments, as expected; in addition, it revealed the exact
amount of remaining polyclonal Ig of paraprotein class,
as well as the patient’s light chain restriction.
We showed here that iHLC-IgG related to parameters
of disease activity, severity and tumor burden, including
anemia, sFLCR and extensive bone marrow infiltration,
while HLCR with the same plus increased b2Μ. Usually,
when such correlations are obtained with the aforemen-
tioned markers, relationship with prognosis is also
found. In our study, this was proven true, and the ratio
of involved/uninvolved Ig (HLCR) correlated with time
to treatment, and most importantly with outcome; thus,
patients with “high” HLCR had a significantly shorter
survival. The improved prognostic information given by
HLCR compared to “total” Igs probably relates to biased
classical Igs measurement in some cases, as discussed
Table 1 HLC-IgG, -IgA and HLCR Results in 130 Healthy
Individuals
Median 95th Percentile range
IgG kappa (g/L) 6.85 4.03-9.78
IgG lambda (g/L) 3.81 1.97-5.71
IgG kappa/IgG lambda HLCR 1.87 0.98-2.75
IgG lambda/IgG kappa HLCR 0.54 0.37-0.893
IgA kappa (g/L) 1.19 0.48-2.82
IgA lambda (g/L) 0.98 0.36-1.98
IgA kappa/IgA lambda HLCR 1.27 0.80-2.04
IgA lambda/IgA kappa HLCR 0.79 0.49-1.256
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earlier; also because polyclonal, non-tumour Ig are
included in “total” Ig quantification. HLCR importance
for progression free survival was recently reported by
others [10]. We additionally confirmed that polyclonal
immunosuppression (in the form of systemic immuno-
paresis or immunoparesis of the same class or both) was
related to time to treatment [11]; although it had no
impact on overall survival. The importance of IgM with
regard to survival was recently reported by Perosa et al
[12]; nevertheless, IgM levels determined by conven-
tional method did not carry any prognostic information
in this series.
Myeloma cells from individual bone marrow biopsies
can produce either “intact” immunoglobulins, free light
chains, or both [13], allowing presumption that the
prognostic information provided by the new M-compo-
nent-based markers (FLC and HLC) could be comple-
mentary; however, in this study, sFLCR and HLCR
strongly correlated and their respective prognostic
power was equivalent.
Both albumin and beta2-microglobulin (b2Μ) are
linked to IgG metabolism via FcRn molecules. b2Μ is
the light chain component of the heterodimeric FcRn
receptor, while albumin is recycled via the same mole-
cule [7]. We speculate that some of the clinical utility of
albumin and b2Μ in the ISS may be linked to IgG meta-
bolism. In our study, HL IgG was related to albumin but
not to b2Μ, although “high” HLCR correlated with
increased b2Μ.
Other disease parameters with an adverse prognostic
impact in this series were, as expected [2], ISS stage [9],
FLCR above median [14], b2Μ above 5, 5 mg/L [15],
albumin below 3.5 g/L [16], haemoglobin below 10 g/L,
platelet counts below 140 × 10 [9]/L [17], serum creati-
nine above 2 mg/L [18] and extensive BM plasma cell
infiltration. Significantly, in multivariate analysis only
platelets, b2M and HLCR retained their statistical
significance.
In conclusion, we provide evidence that HLCR
values correlate with adverse markers and are them-
selves independently prognostic in patients with MM.
Thus, by having the quadruple advantage of determin-
ing separately the kappa- and lambda-bounded
amounts of circulating IgG and IgA, of assessing the
light chain restriction as well as the depth of suppres-
sion of the polyclonal Ig of the same and of the unin-
volved class, and of contributing to prognostication,
the new intact Ig HLC assay, Hevylite™, may concei-
vably replace “classical” total Ig quantitative measure-




Figure 1 “High” or “Low” HLCR in MM patients at diagnosis.
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Figure 2 Time to treatment according (A) to the presence or absence of ISC and (B) SI.
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analyses of larger patient cohorts are necessary for
further validation.
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